一项将聚赖氨酸生物载体与维生素A和C结合的顺序皮肤美容治疗的耐受性和有效性的前瞻性开放标签研究

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL

Health Science Reports Pub Date : 2025-04-16 DOI:10.1002/hsr2.70676

Bertrand Nassar, Hafid Belhadj-Tahar, Weiyang Jin, Guanghua Yang

{"title":"一项将聚赖氨酸生物载体与维生素A和C结合的顺序皮肤美容治疗的耐受性和有效性的前瞻性开放标签研究","authors":"Bertrand Nassar, Hafid Belhadj-Tahar, Weiyang Jin, Guanghua Yang","doi":"10.1002/hsr2.70676","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Objectives</h3>\n \n <p>Atopic dermatitis (AD) is a common chronic inflammatory skin condition, affecting 15%–20% of children and up to 10% of adults. It has a significant impact on patients' quality of life and represents a considerable burden on healthcare systems. Management strategies aim to restore the skin barrier, reduce inflammation, and achieve physiological and homeostatic balance. This study evaluates the safety and efficacy of a new dermocosmetic formulation combining poly-<span>l</span>-lysine biovectors with vitamins A and C.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A single-arm, open-label study was conducted on 20 patients diagnosed with AD, including 14 women and 6 men aged between 24 and 63, with skin phototypes of Fitzpatrick I–VI. Treatment involved sequential application of poly-<span>l</span>-lysine G2/vitamin C in the morning and poly-<span>l</span>-lysine G3/vitamin A in the evening for 28 days, on the face, hands, and body. Outcomes were assessed using the Dermatology Life Quality Index (DLQI) and SCORAD scores. Additional assessments included a visual analog scale for pruritus and sleep disturbance, as well as patient self-report questionnaires on skin improvement and treatment satisfaction.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The treatment was well-tolerated, with no adverse effects and no relapses of AD. After 28 days, patients showed a significant reduction in DLQI (−61.8%, Cohen's <i>d</i> = 1.20) and SCORAD (−41.8%, Cohen's <i>d</i> = 1.05) scores. Objective improvements included reductions in erythema (−50%), dryness (−60%), and pruritus (−50%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study demonstrates the potential of poly-<span>l</span>-lysine-based dermocosmetics combined with vitamins A and C to improve the symptoms and quality of life of patients suffering from AD. The formulations were well-tolerated and effective in restoring the skin barrier and reducing inflammation. Further large-scale controlled studies are needed to validate these results and explore long-term efficacy.</p>\n </section>\n </div>","PeriodicalId":36518,"journal":{"name":"Health Science Reports","volume":"8 4","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hsr2.70676","citationCount":"0","resultStr":"{\"title\":\"A Prospective Open-Label Study of Tolerance and Effectiveness of Sequential Dermocosmetic Treatments Combining Poly-l-Lysine Biovectors With Vitamins A and C\",\"authors\":\"Bertrand Nassar, Hafid Belhadj-Tahar, Weiyang Jin, Guanghua Yang\",\"doi\":\"10.1002/hsr2.70676\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Objectives</h3>\\n \\n <p>Atopic dermatitis (AD) is a common chronic inflammatory skin condition, affecting 15%–20% of children and up to 10% of adults. It has a significant impact on patients' quality of life and represents a considerable burden on healthcare systems. Management strategies aim to restore the skin barrier, reduce inflammation, and achieve physiological and homeostatic balance. This study evaluates the safety and efficacy of a new dermocosmetic formulation combining poly-<span>l</span>-lysine biovectors with vitamins A and C.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A single-arm, open-label study was conducted on 20 patients diagnosed with AD, including 14 women and 6 men aged between 24 and 63, with skin phototypes of Fitzpatrick I–VI. Treatment involved sequential application of poly-<span>l</span>-lysine G2/vitamin C in the morning and poly-<span>l</span>-lysine G3/vitamin A in the evening for 28 days, on the face, hands, and body. Outcomes were assessed using the Dermatology Life Quality Index (DLQI) and SCORAD scores. Additional assessments included a visual analog scale for pruritus and sleep disturbance, as well as patient self-report questionnaires on skin improvement and treatment satisfaction.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The treatment was well-tolerated, with no adverse effects and no relapses of AD. After 28 days, patients showed a significant reduction in DLQI (−61.8%, Cohen's <i>d</i> = 1.20) and SCORAD (−41.8%, Cohen's <i>d</i> = 1.05) scores. Objective improvements included reductions in erythema (−50%), dryness (−60%), and pruritus (−50%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study demonstrates the potential of poly-<span>l</span>-lysine-based dermocosmetics combined with vitamins A and C to improve the symptoms and quality of life of patients suffering from AD. The formulations were well-tolerated and effective in restoring the skin barrier and reducing inflammation. Further large-scale controlled studies are needed to validate these results and explore long-term efficacy.</p>\\n </section>\\n </div>\",\"PeriodicalId\":36518,\"journal\":{\"name\":\"Health Science Reports\",\"volume\":\"8 4\",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hsr2.70676\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Science Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70676\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Science Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的特应性皮炎（AD）是一种常见的慢性炎症性皮肤病，影响15%-20%的儿童和高达10%的成人。它对患者的生活质量产生重大影响，并对医疗保健系统构成相当大的负担。治疗策略旨在恢复皮肤屏障，减少炎症，达到生理和体内平衡。本研究评估了一种将聚赖氨酸生物载体与维生素a和c结合的新型皮肤化妆品配方的安全性和有效性。方法对20例AD患者进行单臂、开放标签研究，其中女性14例，男性6例，年龄24 ~ 63岁，皮肤光型为Fitzpatrick I-VI。治疗包括在早晨使用聚赖氨酸G2/维生素C，在晚上使用聚赖氨酸G3/维生素A，连续使用28天，涂抹于面部、手部和身体。使用皮肤病生活质量指数（DLQI）和SCORAD评分评估结果。其他评估包括瘙痒和睡眠障碍的视觉模拟量表，以及患者关于皮肤改善和治疗满意度的自我报告问卷。结果治疗耐受性好，无不良反应，无AD复发。28天后，患者DLQI评分（- 61.8%,Cohen’s d = 1.20）和SCORAD评分（- 41.8%,Cohen’s d = 1.05）均显著降低。客观改善包括红斑（- 50%）、干燥（- 60%）和瘙痒（- 50%）的减少。结论以聚赖氨酸为基础的皮肤化妆品联合维生素A和C可改善AD患者的症状和生活质量。该配方耐受性良好，在恢复皮肤屏障和减少炎症方面有效。需要进一步的大规模对照研究来验证这些结果并探索长期疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Prospective Open-Label Study of Tolerance and Effectiveness of Sequential Dermocosmetic Treatments Combining Poly-l-Lysine Biovectors With Vitamins A and C

Background and Objectives

Atopic dermatitis (AD) is a common chronic inflammatory skin condition, affecting 15%–20% of children and up to 10% of adults. It has a significant impact on patients' quality of life and represents a considerable burden on healthcare systems. Management strategies aim to restore the skin barrier, reduce inflammation, and achieve physiological and homeostatic balance. This study evaluates the safety and efficacy of a new dermocosmetic formulation combining poly-l-lysine biovectors with vitamins A and C.

Methods

A single-arm, open-label study was conducted on 20 patients diagnosed with AD, including 14 women and 6 men aged between 24 and 63, with skin phototypes of Fitzpatrick I–VI. Treatment involved sequential application of poly-l-lysine G2/vitamin C in the morning and poly-l-lysine G3/vitamin A in the evening for 28 days, on the face, hands, and body. Outcomes were assessed using the Dermatology Life Quality Index (DLQI) and SCORAD scores. Additional assessments included a visual analog scale for pruritus and sleep disturbance, as well as patient self-report questionnaires on skin improvement and treatment satisfaction.

Results

The treatment was well-tolerated, with no adverse effects and no relapses of AD. After 28 days, patients showed a significant reduction in DLQI (−61.8%, Cohen's d = 1.20) and SCORAD (−41.8%, Cohen's d = 1.05) scores. Objective improvements included reductions in erythema (−50%), dryness (−60%), and pruritus (−50%).

Conclusion

This study demonstrates the potential of poly-l-lysine-based dermocosmetics combined with vitamins A and C to improve the symptoms and quality of life of patients suffering from AD. The formulations were well-tolerated and effective in restoring the skin barrier and reducing inflammation. Further large-scale controlled studies are needed to validate these results and explore long-term efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊